NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Core Insights - The article discusses advancements in Nanobiotix's Curadigm Nanoprimer platform, which aims to enhance the delivery of therapeutic agents for cancer and other diseases [1][2][3] Company Developments - Nanobiotix has filed four new patent applications to strengthen the intellectual property foundation of the Curadigm platform, supporting both internal product development and external collaborations [4][5][8] - The Curadigm Nanoprimer is designed to improve the extrahepatic delivery of IV-administered therapeutic agents, potentially increasing efficacy and reducing liver-related toxicity [2][10][13] Research and Data - New preclinical data presented at the 2025 Partnership Opportunities in Drug Delivery conference indicates that the Nanoprimer enhances immune response when used with mRNA and peptide-based vaccines [6][7][9][17] - The findings suggest a new pathway for IV-administered therapeutic vaccines, particularly in oncology, and will form the basis for Nanobiotix's initial proprietary pipeline of Nanoprimer products [9][10][11] Strategic Collaborations - Nanobiotix is actively pursuing collaborations and has established numerous material transfer agreements with biotechnology and pharmaceutical partners to explore Nanoprimer combinations [11][12]